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A B S T R A C T
Aims: To determine the prevalence of and risk factors for diabetes mellitus and examine its
diagnosis and management in the study communities.
Methods: This is a population-based cross-sectional study among adults in 24 communities
from Zambia and the Western Cape (WC) province of South Africa. Diabetes is defined as a
random blood glucose concentration (RBG)P 11.1 mmol/L, or RBG < 11.1 mmol/L but with a
self-reported prior diabetes diagnosis. For individuals with a prior diagnosis of diabetes,
RBG < 7.8 mmol/L was considered to be an acceptable level of glycaemia.
Results: Among 45,767 Zambian and 12,496 WC participants the age-standardised preva-
lence of diabetes was 3.5% and 7.2% respectively. The highest risk groups identified were
those of older age and those with obesity. Of those identified to have diabetes, 34.5% in
Zambia and 12.7% in WC were previously unaware of their diagnosis. Among Zambian par-
ticipants with diabetes, this proportion was lower among individuals with better education
or with higher household socio-economic position. Of all those with previously diagnosed
diabetes, 66.0% in Zambia and 59.4% in WC were not on any diabetes treatment, and 34.4%
in Zambia and 32.7% in WC had a RBG concentration beyond the recommended level,
P7.8 mmol/L.
Conclusions: The diabetes risk factor profile for our study communities is similar to that
seen in high-income populations. A high proportion of individuals with diabetes are not
on diabetes treatment and of those on treatment a high proportion have high glycaemic
concentrations. Such data may assist in healthcare planning to ensure timely diagnosis
and management of diabetes.
 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the
CC BY license (http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
The number of adults with diabetes mellitus in sub-Saharan
Africa (SSA) is predicted to rise from 19.8 million in 2013 to
41.5 million in 2035 [1–5]. Extensive data exist to guide dia-
betes public health policies and health systems planning in
high income countries [6–8]. In contrast, systematic review
suggests there are few data from SSA even for diabetes preva-
lence and risk factors [1,9–12].
The management of diabetes can be challenging for health
systems, as it requires lifelong follow-up and a multidisci-
plinary approach [3,13,14]. Therefore, the aims of this study
are
 to estimate the prevalence of, and identify risk factors
for, diabetes mellitus in the study communities in
Zambia and in the Western Cape province of South
Africa; and
 to estimate the prevalence of undiagnosed diabetes, to
determine the proportion of those with a prior diagno-
sis of diabetes who are on treatment for diabetes, and
to determine the levels of glycaemia in those with a
prior diagnosis of diabetes.
2. Methods
This population-based cross-sectional study was undertaken
between January and December 2010 in 24 communities: 16
from 5 provinces in Zambia and 8 from the Western Cape pro-
vince of South Africa. The study was nested into a prevalence
survey that was conducted to measure the primary endpoint,
prevalent tuberculosis, of a large 2  2 factorial cluster ran-
domised trial (the ZAMSTAR study) [15–17]. The estimated
total population in the study areas was 962,655, with an aver-
age population per community of 40,110. Within each com-
munity, a two-stage cluster sampling design was used to
recruit participants. Exclusion criteria were age <18 years,
inability to give informed consent due to disability/incapaci-
tation, refusal to submit a respiratory sample – for purposes
of the parent study – and any persons living in institutional
settings.
Each participant was required to give written informed
consent. Individuals and household heads were interviewed
in their homes using structured questionnaires. Finger prick
capillary blood was taken for HIV testing and random blood
glucose (RBG) measurement, with pre- and post-test coun-
selling for HIV tests. Determine TMHIV-1/2 was used for HIV
testing, plus UniGoldTMHIV-1/2 to confirm all positives. RBG
concentration was measured using an Optium Xceed point-
of-care glucometer. All research staff were trained on the
use of this particular glucometer and were required to
undergo proficiency testing. Standardised control solution
was used for performance checks on test strips and meters.
Height and weight were measured using standard operating
procedures. All individuals identified to have abnormal blood
glucose or to be HIV positive were referred to existing local
health facilities for appropriate management.
Data were electronically entered directly onto personal
digital assistants by field staff at the time of data collection,
using pre-programmed questionnaires and result sheets. All
information was downloaded daily into a SQL (structured
query language) database and later exported into Stata.
Ethics approval was granted from the London School of
Hygiene and Tropical Medicine Ethics Committee, the Univer-
sity of Stellenbosch Ethics Committee and the University of
Zambia Ethics Committee.
2.1. Definitions
 Diabetes mellitus was defined as a random blood glu-
cose concentration (RBG)P 11.1 mmol/L, or
RBG < 11.1 mmol/L but with a self-reported prior dia-
betes diagnosis.
 Body mass index (BMI) was defined as weight in kilo-
grams divided by height squared in metres (weight
(kg)/height2(m)).
 HIV status was defined by a combination of blood
sampling and self-report for those with missing bio-
logical data.
 Exposures (risk factors) for diabetes were defined as
proximal or distal factors. Distal factors include age,
sex, household socio-economic position, education,
smoking history, HIV status and community. The
proximal factor, BMI, may be determined partly by
the distal factors and so estimation of its direct effect
on diabetes requires controlling for confounding by
the more distal factors.
 For assessing the management of those with diabetes,
RBG < 7.8 mmol/L was considered to be the recom-
mended level of glycaemia, as specified by the Interna-
tional Diabetes Federation guideline for target
postprandial glucose concentration [18].
2.2. Statistical analyses
Direct age standardisation for the prevalence of diabetes was
calculated by applying the study age-specific diabetes rates
(separately for Zambia and the Western Cape) to the 2013
International Network for the Demographic Evaluation of
Populations and Their Health (INDEPTH) sub-Saharan African
standard population distribution. Univariable and multivari-
able logistic regression analyses were used to identify risk fac-
tors for diabetes, accounting for the cluster sampling design.
Principal components analysis was used to create a measure
of household socio-economic position separately for each
country, using the following variables: main type of dwelling;
main type of flooring; main type of household toilet; main
source of household drinking water, and presence of house-
hold assets including radio, television, refrigerator, bicycle,
motorcycle, car, domestic worker and mobile phone.
The variables considered a priori as potential risk factors
were those known to be risk factors in other populations
and settings [19,20]: age, sex, household socio-economic posi-
tion, education, smoking, ethnicity and adiposity (measured
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by BMI). HIV status was also considered given its high preva-
lence in both localities, and the known effects of some
antiretroviral medications on insulin resistance [21]. Rural/
urban location was not considered as a binary variable as a
finer categorisation of location was required to account for
between-community variation in analysis of household and
individual-level risk factors.
Household socio-economic position and individual educa-
tion are expected to be inter-related. For the analyses pre-
sented here, education was considered to be the more distal
variable and we explored whether the association between
education and diabetes prevalence was partly mediated by
household wealth.
Body mass index was considered to be a factor that is
proximal to household socio-economic position and educa-
tion on the causal pathway to diabetes, and also to age, sex
and HIV status. To estimate the association of these more dis-
tal factors with the outcome (to identify high risk groups) it
was important first to exclude the measure of obesity from
multivariable analyses, and secondly to include it so as to
identify how much of any observed associations were medi-
ated by BMI. Therefore, separate final models were created,
with andwithout inclusion of BMI. All data analyses were per-
formed using Stata12.
3. Results
In Zambia, 57,809 (70.8% of eligible) participants from 31,300
(88.6% of eligible) households were enrolled. In Western Cape,
32,792 (77.7% of eligible) participants from 17,095 (85.3% of eli-
gible) households were enrolled (Fig. 1). Complete RBG results
were obtained for 45,767 (79.2% of enrolled) participants in
Zambia and 12,496 (38.1% of enrolled) participants in Western
Cape. Among all participants with an RBG measurement
(those forming the final dataset for analyses) 524 (1.1%) in
Zambia and 9 (0.1%) in Western Cape had missing data for
age, 3883 (8.5%) and 788 (6.3%) respectively had missing data
for HIV status, and 3536 (7.7%) and 365 (2.9%) respectively
had missing data for BMI.
The distribution of the baseline characteristics for all par-
ticipants who contributed to the analyses is shown in Tables 1
and 2. The study participants ranged between ages 18–102
(mean 33.3 years) years in Zambia and 18–103 years (mean
37.0 years) in Western Cape. Two-thirds of the participants
were female in both countries. The distribution of the base-
line characteristics for participants with missing glycaemia
data are given in a supplementary table. The only large differ-
ence in distribution of individuals with and without gly-
caemia data occurred for the community variable.
3.1. Prevalence
Fig. 2 shows the numbers of people with diabetes according to
self-report and positive screen. In Zambia 65.5% (870/1329) of
people with diabetes were previously diagnosed whereas in
Western Cape the figure was 87.3% (1029/1179). The preva-
lence of diabetes mellitus among study participants in Zam-
bia was 2.9% and in Western Cape 9.4%. Diabetes prevalence
stratified by baseline characteristics is shown in Tables 1
and 2. The prevalence was highest in older participants and
in those with a higher body mass index.
The INDEPTH sub-Saharan African standard population
age-standardised prevalence of diabetes mellitus was 3.5%
for the Zambian communities and 7.2% for the Western Cape
communities.
3.2. Risk factors
After multivariable analyses (Tables 1 and 2), the distal risk
factors for diabetes mellitus identified in these study popula-
tions were age, sex, household socio-economic position, HIV
status, and community for Zambia, and age, sex, smoking,
HIV status and community for the Western Cape communi-
ties, with age being the strongest predictor in both settings.
In Zambia the association between education and diabetes
was strongly confounded by age; after adjusting for age the
odds of diabetes increased with education level, and the
strong confounding was due to the better educated being
younger, on average. The odds of diabetes also increased with
higher household socio-economic position in Zambia, and
this explained some of the association between education
and diabetes (ORs for education grade 3–6, 7–10, 11–12, and
College/University were 1.22, 1.39, 1.62, and 1.87, p < 0.001,
with adjustment for age, sex, community, smoking and HIV
but not household socio-economic position). Ethnicity was
not identified as a risk factor and was not included in the final
multivariable model as it varied little within communities in
the Western Cape so that community and ethnicity effects
could not be distinguished, and varied little across all the
Zambian communities.
There was strong evidence that the proximal risk factor,
BMI, was associated with diabetes in both Zambia and the
Western Cape communities. Comparison of the models with
and without controlling for BMI shows that after adjustment
for BMI the higher odds of diabetes among women compared
with men is no longer seen for Zambian participants (Table 1)
and is slightly reduced in Western Cape participants (Table 2).
The association seen between smoking history and diabetes
in Western Cape participants is also reduced. The associa-
tions with age in both countries, household socio-economic
position in Zambian communities, and HIV status in Western
Cape communities remain after accounting for the measure
of adiposity, but are all reduced in magnitude.
When HIV status is further sub-divided by current use or
not of antiretroviral therapy (ART), the odds of diabetes in
Western Cape communities is lowest in the group who are
HIV positive but not on ART: ORs for HIV negative, HIV posi-
tive not on ART and HIV positive on ART were 1, 0.69, and
1.03, p = 0.006, with adjustment for all proximal and distal
factors. No association remains for the Zambian
communities.
Using self-report rather than the RBG-based definition
used for the rest of this study removes potential biases result-
ing from the use of RBG as the measurement tool and simul-
taneously increases the number of participants without
missing data in the fully adjusted models to 43,060 in Zambia
and 11,508 in theWestern Cape. Of note, fitting the samemul-
tivariable models but with the outcome of diabetes defined
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entirely by self-report showed that odds ratios and evidence
for associations were similar to the findings summarised in
Tables 1 and 2. Likewise, redefining diabetes to include only
those with RBGP 11.1 mmol/L plus those on treatment for
diabetes regardless of their RBG concentration confirms the
main risk factor profile identified. This definition removes
the group who have self-reported diabetes but are not on
treatment for diabetes and have a RBG < 11.1 mmol/L. Age
and BMI are again identified as the main risk factors for dia-
betes, and sex is no longer identified as a risk factor in Wes-
tern Cape.
3.3. Diagnosis and management
Fig. 2 shows for Zambia and Western Cape the numbers of
participants with diabetes by self-report and RBG diagnosis,
along with numbers on treatment for diabetes.
The prevalence of undiagnosed diabetes among the total
study population, including among those without diabetes,
was 1.0% in the Zambian sites and 1.2% in the Western Cape
sites. Stratification by participant characteristics for the
prevalence of undiagnosed diabetes among all those with dia-
betes is shown in Table 3. Strong evidence for unadjusted
association with undiagnosed diabetes is seen for household
socio-economic position, education and community in the
Zambia sites, and age and community in the Western Cape
sites.
Of all those who had a prior diabetes diagnosis, 34.0% in
Zambia and 40.6% in Western Cape were on diabetes treat-
ment consisting of either dietary management, hypogly-
caemic tablets or insulin therapy (Table 4). Among those
with a prior diagnosis who were on diabetes treatment, the
mean random blood glucose concentration for Zambian par-
ticipants was 12.8 mmol/L (standard deviation, SD,
6.6 mmol/L). The corresponding mean for Western Cape par-
ticipants was 11.0 mmol/L (SD 5.8 mmol/L). Among thosewith
a prior diagnosis whowere not on any diabetes treatment, the
mean RBG concentration for Zambian participants was
Fig. 1 – Number and flow of study participants and cases in Zambia and the Western Cape of South Africa.
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Table 1 – Prevalence of diabetes mellitus in the Zambian sites, with corresponding unadjusted and adjusted odds ratios estimated by logistic regression, showing
adjustment for distal risk factors (without measure of adiposity) and more proximal factor (body mass index).
Characteristic Total
number (%)
Number (%)
with DM*
Unadjusted
OR (95% CI)
P-value# Adjusted OR
excluding
BMI (95% CI)+
P-value# Adjusted OR
including
BMI (95% CI)
++
P-value#
Overall 45,767 (100) 1329 (2.9)
Age (years) 18–24 15,983 (35.3) 202 (1.3) 1 <0.001 (TFT p < 0.001) 1 <0.001 (TFT p < 0.001) 1 <0.001 (TFT p < 0.001)
25–29 7590 (16.8) 107 (1.4) 1.09 (0.86–1.39) 1.12 (0.88-1.43) 1.04 (0.81–1.35)
30–34 5583 (12.3) 122 (2.2) 1.70 (1.35–2.13) 1.73 (1.36–2.21) 1.53 (1.19–1.98)
35–39 3971 (8.8) 106 (2.7) 2.23 (1.76–2.84) 2.38 (1.84–3.07) 2.08 (1.59–2.73)
40–49 5195 (11.5) 232 (4.5) 3.80 (3.13–4.61) 3.89 (3.14–4.81) 3.03 (2.40–3.81)
50–59 3540 (7.8) 277 (7.8) 7.19 (5.95–8.69) 7.50 (6.08–9.26) 5.86 (4.67–7.36)
60+ 3381 (7.5) 256 (7.6) 7.23 (5.96–8.77) 7.93 (6.27–10.03) 6.79 (5.29–8.72)
Sex Male 15,153 (33.1) 403 (2.7) 1 0.022 1 0.010 1 0.893
Female 30,614 (66.9) 926 (3.0) 1.15 (1.02–1.30) 1.22 (1.05–1.43) 0.99 (0.84–1.17)
Household
socio-economic
position
Very low 10,571 (23.1) 229 (2.2) 1 <0.001 (TFT p < 0.001) 1 <0.001 (TFT p < 0.001) 1 <0.001 (TFT p < 0.001)
Low 12,058 (26.4) 331 (2.8) 1.22 (1.01–1.46) 1.31 (1.07–1.60) 1.23 (1.00–1.53)
Medium 11,570 (25.3) 366 (3.2) 1.46 (1.20–1.77) 1.60 (1.29–1.98) 1.45 (1.16–1.83)
High 11,568 (25.3) 403 (3.5) 1.83 (1.46–2.30) 2.02 (1.57–2.62) 1.79 (1.37–2.34)
Highest level
of education
None/grade 1-2 3507 (7.7) 142 (4.1) 1 <0.001 (TFT p < 0.001) 1 0.074 (TFT p = 0.004) 1 0.089 (TFT p = 0.008)
Grade 3-6 5753 (12.6) 191 (3.3) 0.81 (0.65–1.02) 1.21 (0.92–1.58) 1.26 (0.94–1.68)
Grade 7–10 22,486 (49.1) 642 (2.9) 0.61 (0.50–0.73) 1.30 (1.01–1.66) 1.35 (1.04–1.77)
Grade 11–12 9947 (21.7) 201 (2.0) 0.40 (0.32–0.51) 1.42 (1.06–1.92) 1.49 (1.09–2.05)
College/University 4074 (8.9) 153 (3.8) 0.72 (0.57–0.93) 1.56 (1.14–2.14) 1.56 (1.12–2.18)
Smoking history Never 39,743 (86.8) 1170 (2.9) 1 0.583 (TFT p = 0.334) 1 0.169 (TFT p = 0.071) 1 0.397 (TFT p = 0.194)
Ex-smoker 2319 (5.1) 70 (3.0) 0.99 (0.77–1.28) 0.96 (0.72–1.27) 0.97 (0.73–1.29)
Current smoker 3705 (8.1) 89 (2.4) 0.89 (0.71–1.11) 0.78 (0.59–1.02) 0.83 (0.63–1.09)
HIV status** Negative 36,643 (82.7) 947 (2.7) 1 0.169 1 0.041 1 0.646
Positive 7241 (17.3) 202 (2.8) 0.90 (0.77–1.05) 0.84 (0.71–0.99) 0.96 (0.81–1.14)
Body Mass Index***
(weight(kg)/height2(m))
Recommended
weight (18.5–24.9)
26,865 (63.6) 537 (2.0) 1 <0.001 (TFT p < 0.001)## 1 <0.001 (TFT p < 0.001)##
Underweight (<18.5) 4203 (10.0) 98 (2.3) 1.12 (0.90–1.40) 1.09 (0.86–1.38)
Overweight (25–29.9) 7429 (17.6) 327 (4.4) 2.26 (1.96–2.61) 1.52 (1.29–1.79)
Obese (P30) 3734 (8.8) 268 (7.2) 3.82 (3.27–4.46) 2.29 (1.89–2.77)
Community ZAM1 3675 (8.0) 282 (7.7) 1 <0.001 1 <0.001 1 <0.001
ZAM2 2944 (6.4) 106 (3.6) 0.51 (0.34–0.77) 0.45 (0.29–0.7) 0.45 (0.29–0.70)
ZAM3 (rural) 2516 (5.5) 59 (2.3) 0.37 (0.24–0.56) 0.32 (0.20–0.51) 0.31 (0.19–0.50)
ZAM4 (rural) 1302 (2.8) 26 (2.0) 0.28 (0.16–0.51) 0.26 (0.13–0.51) 0.24 (0.12–0.48)
ZAM5 2844 (6.2) 79 (2.8) 0.41 (0.27–0.62) 0.41 (0.26–0.66) 0.38 (0.24–0.61)
ZAM6 2961 (6.5) 63 (2.1) 0.34 (0.22–0.53) 0.31 (0.19–0.50) 0.29 (0.18–0.48)
ZAM7 3540 (7.7) 94 (2.7) 0.43 (0.28–0.64) 0.46 (0.29–0.72) 0.45 (0.28–0.70)
ZAM8 3646 (8.0) 78 (2.1) 0.33 (0.22–0.52) 0.38 (0.24–0.60) 0.36 (0.22–0.59)
ZAM9 2145 (4.7) 56 (2.6) 0.39 (0.25–0.61) 0.26 (0.16–0.43) 0.27 (0.16–0.46)
ZAM10 2392 (5.2) 59 (2.5) 0.37 (0.24–0.57) 0.48 (0.29–0.78) 0.48 (0.27–0.85)
ZAM11 3092 (6.8) 94 (3.0) 0.48 (0.31–0.72) 0.31 (0.20–0.50) 0.31 (0.19–0.49)
ZAM12 3401 (7.4) 82 (2.4) 0.39 (0.25–0.58) 0.26 (0.16–0.40) 0.25 (0.16–0.40)
ZAM13 3032 (6.6) 73 (2.4) 0.35 (0.23–0.54) 0.28 (0.18–0.44) 0.29 (0.18–0.45)
ZAM14 2760 (6.0) 58 (2.1) 0.32 (0.20–0.49) 0.37 (0.23–0.61) 0.35 (0.21–0.57)
ZAM15 (rural) 2865 (6.3) 64 (2.2) 0.36 (0.22–0.59) 0.33 (0.19–0.56) 0.34 (0.20–0.59)
ZAM16 (rural) 2652 (5.8) 56 (2.1) 0.33 (0.21–0.53) 0.35 (0.21–0.58) 0.38 (0.22–0.63)
DM = diabetes mellitus; CI = confidence interval; OR = odds ratio; TFT = likelihood ratio test for trend with exposure as a linear variable; All analyses accounted for the two-stage clustered sampling
design through use of a logistic regression model with random effects for enumeration area and inclusion of community as a fixed-effect.
+
41,475 participants included in analysis, adjusted for age, sex, household socio-economic position, education, smoking, HIV status and community.
++
38,250 participants included in analysis, adjusted for all variables shown; Missing data: 524 for age, 3883 for HIV status, 3536 for BMI.
# Likelihood ratio tests.
## Tests for linear trend and departure from linearity calculated with underweight as the baseline group.
* Defined as a random blood glucose concentration of P11.1 mmol/L or <11.1 mmol/L with self-reported previous DM diagnosis.
** Based on serology plus self-report for those with no available serology.
*** Grouped according to the International BMI Classification.
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Table 2 – Prevalence of diabetes mellitus in the Western Cape sites, with corresponding unadjusted and adjusted odds ratios estimated by logistic regression, showing
adjustment for distal risk factors (without measure of adiposity) and more proximal factor (body mass index).
Characteristic Total
number (%)
Number (%)
with DM*
Unadjusted
OR (95% CI)
P-value# Adjusted OR
excluding
BMI (95% CI)+
P-value# Adjusted OR
including
BMI (95% CI)++
P-value#
Overall 12,496 (100) 1179 (9.4)
Age (years) 18–24 3207 (25.7) 115 (3.6) 1 <0.001 (TFT p < 0.001) 1 <0.001 (TFT p < 0.001) 1 <0.001 (TFT p < 0.001)
25–29 1810 (14.5) 78 (4.3) 1.21 (0.90–1.63) 1.30 (0.96–1.76) 1.16 (0.86–1.58)
30–34 1456 (11.7) 75 (5.2) 1.48 (1.10–2.00) 1.59 (1.17-2.17) 1.41 (1.03–1.93)
35–39 1290 (10.3) 103 (8.0) 2.34 (1.78–3.09) 2.40 (1.80–3.19) 2.03 (1.51–2.72)
40–49 2090 (16.7) 240 (11.5) 3.48 (2.76–4.39) 3.40 (2.65–4.37) 2.88 (2.22–3.72)
50–59 1454 (11.6) 263 (18.1) 5.94 (4.71–7.50) 5.37 (4.12–6.99) 4.36 (3.32–5.72)
60+ 1180 (9.5) 305 (25.9) 9.95 (7.88–12.56) 9.30 (7.07–12.25) 7.63 (5.75–10.12)
Sex Male 4155 (33.3) 251 (6.0) 1 <0.001 1 <0.001 1 <0.001
Female 8341 (66.7) 928 (11.1) 1.97 (1.70–2.28) 1.95 (1.65–2.30) 1.62 (1.35–1.93)
Household socio-economic
position
Very low 2823 (22.6) 188 (6.7) 1 <0.001 (TFT p < 0.001) 1 0.149 (TFT p = 0.067) 1 0.287 (TFT p = 0.153)
Low 3350 (26.8) 298 (8.9) 1.35 (1.08–1.67) 1.26 (1.00–1.58) 1.21 (0.96–1.53)
Medium 3468 (27.8) 362 (10.4) 1.57 (1.26–1.96) 1.26 (0.99–1.60) 1.25 (0.98–1.59)
High 2855 (22.9) 331 (11.6) 1.61 (1.27–2.04) 1.33 (1.03–1.71) 1.25 (0.96–1.61)
Highest level of education None/grade 1–2 940 (7.5) 151 (16.1) 1 <0.001 (TFT p < 0.001) 1 0.341 (TFT p = 0.483) 1 0.371 (TFT p = 0.231)
Grade 3–6 1876 (15.0) 275 (14.7) 0.85 (0.68–1.06) 1.05 (0.82–1.33) 1.00 (0.78–1.28)
Grade 7–10 4973 (39.8) 503 (10.1) 0.55 (0.45–0.68) 1.05 (0.84–1.33) 0.98 (0.77–1.23)
Grade 11–12 4296 (34.4) 226 (5.3) 0.27 (0.22–0.34) 0.87 (0.66–1.15) 0.81 (0.61–1.08)
College/University 411 (3.3) 24 (5.8) 0.28 (0.18–0.45) 1.10 (0.67–1.80) 1.02 (0.62–1.69)
Smoking history Never 9248 (74.0) 937 (10.1) 1 <0.001 (TFT p < 0.001) 1 0.004 (TFT p = 0.002) 1 0.041 (TFT p = 0.090)
Ex-smoker 2406 (19.3) 204 (8.5) 0.69 (0.59–0.82) 0.87 (0.72–1.06) 1.01 (0.83–1.23)
Current smoker 842 (6.7) 38 (4.5) 0.44 (0.31–0.62) 0.57 (0.40–0.82) 0.63 (0.43–0.92)
HIV status** Negative 9610 (82.1) 983 (10.2) 1 <0.001 1 <0.001 1 0.008
Positive 2098 (17.9) 124 (5.9) 0.57 (0.47–0.69) 0.69 (0.57–0.85) 0.76 (0.62–0.93)
Body Mass Index***
(weight(kg)/height2(m))
Recommended
weight (18.5–24.9)
4732 (39.0) 251 (5.3) 1 <0.001 (TFT p < 0.001)## 1 <0.001 (TFT p < 0.001)##
Underweight (<18.5) 678 (5.6) 37 (5.5) 1.00 (0.70–1.43) 0.87 (0.60–1.27)
Overweight (25–29.9) 2859 (23.6) 298 (10.4) 2.09 (1.75–2.49) 1.47 (1.21–1.78)
Obese (P30) 3862 (31.8) 549 (14.2) 3.00 (2.56–3.51) 1.78 (1.47–2.14)
Community WC1 1258 (10.1) 169 (13.4) 1 <0.001 1 <0.001 1 <0.001
WC2 2440 (19.5) 266 (10.9) 0.78 (0.56–1.07) 0.96 (0.68–1.35) 0.96 (0.69–1.36)
WC3 (rural) 212 (1.7) 12 (5.7) 0.36 (0.18–0.74) 0.70 (0.33–1.51) 0.72 (0.34–1.56)
WC4 1809 (14.5) 186 (10.3) 0.76 (0.54–1.05) 1.27 (0.89–1.80) 1.25 (0.88-1.78)
WC5 1275 (10.2) 59 (4.6) 0.32 (0.21–0.48) 0.47 (0.30–0.72) 0.48 (0.31–0.74)
WC6 (rural) 2684 (21.5) 209 (7.8) 0.56 (0.41–0.77) 0.57 (0.41–0.80) 0.56 (0.40–0.79)
WC7 1702 (13.6) 129 (7.6) 0.57 (0.40–0.80) 0.75 (0.52–1.09) 0.73 (0.51–1.07)
WC8 1116 (8.9) 149 (13.4) 1.02 (0.74–1.42) 1.28 (0.90–1.81) 1.30 (0.91–1.85)
DM = diabetes mellitus; CI = confidence interval; OR = odds ratio; TFT = likelihood ratio test for trend with exposure as a linear variable; DFL = likelihood ratio test for departure from linear trend; All
analyses accounted for the two-stage clustered sampling design through use of a logistic regression model with random effects for enumeration area and inclusion of community as a fixed effect.
+ 11,699 participants included in analyses, adjusted for age, sex, household socio-economic position, education level, smoking history and HIV status.
++ 11,365 participants included in analysis, adjusted for all variables shown; Missing data: 9 for age, 788 for HIV status, 365 for BMI.
# Likelihood ratio tests.
## Tests for linear trend and departure from linearity calculated with underweight as the baseline group.
* Defined as a random blood glucose concentration of P11.1 mmol/L or <11.1 mmol/L but with self-reported previous DM diagnosis.
** Based on serology plus self-report for those with no available serology.
*** Grouped according to the International BMI Classification.
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6.4 mmol/L (SD 3.0 mmol/L) and for Western Cape partici-
pants was 6.3 mmol/L (SD 2.7 mmol/L). Table 5 shows these
data as numbers of participants by category of RBG
concentration.
4. Discussion
The prevalence of diabetes mellitus in these study communi-
ties rivals that seen in high-income settings [22,23]. After
adjustment for confounding factors, there is strong evidence
that the prevalence of diabetes in participants from both
countries increases with age and BMI, and differs by commu-
nity. Among Zambian participants there is strong evidence
that the prevalence of diabetes increases with increasing
household socio-economic position, and also with level of
education attained when the interrelated effect of household
socio-economic position is not adjusted for.
AmongWestern Cape participants there is strong evidence
that the prevalence of diabetes is higher in females than
males and among those who are HIV negative compared to
those who are HIV positive. Participation was higher in
women than men in all study communities, most likely
because women were more readily found in their homes,
the site of enrolment, than men. The same was true for par-
ticipants who were excluded from the analyses due to miss-
ing glycaemia data (supplementary table) and so is unlikely
to have caused any systematic bias.
BMI, as a measure of adiposity, entirely explains the male–
female differential in diabetes prevalence in the Zambian
sites and most of the association with smoking in the
Western Cape sites, but only partially explains associations
with age, education and household socio-economic position.
These distal factors are therefore associated with diabetes
independently of adiposity, in addition to the mediating path-
way via adiposity. The remaining association with age is
explained by differences in self-reporting of diabetes between
men and women: the association is removed entirely when
the diabetes definition used removes the group who report
that they have diabetes but have RBG < 11.1 mmol/L and are
not on treatment for diabetes.
Of those with diabetes, individuals who are more likely to
have undiagnosed diabetes are those who are older, from a
lower household socio-economic position and with a lower
level of education. Of those with self-reported previously
diagnosed diabetes, many remain on no treatment for their
diabetes, not even dietary management. A high proportion
have high random blood glucose concentrations, though
more so among those who are on treatment for their diabetes
rather than among those who are not on treatment. This
could indicate that those with the most poorly controlled dia-
betes are more likely to be given treatment, even though the
treatment they are given is sub-optimal, or it could reflect
measurement error for self-reported prior diabetes diagnosis.
The risk factor profile seen in this study is similar to that
seen for diabetes elsewhere except for the pattern of associa-
tion seen with HIV status in the Western Cape [11,12,19,24–
26]. A reduced risk of diabetes for those with HIV but not on
antiretroviral therapy is unexpected. It would be more under-
standable for those with HIV and on anti-retroviral
medication to have an enhanced risk of diabetes, due to
Fig. 2 – Numbers of (a) Zambian and (b) Western Cape participants with diabetes by self-report and RBG diagnosis, and
numbers who report they are currently on treatment for diabetes. Legend: treatment = dietary, oral hypoglycaemic agents or
insulin.
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Table 3 – Prevalence of undiagnosed diabetes among all those identified to have diabetes stratified by participant characteristics.
Characteristic Zambian sites Western Cape sites
Number (%) with undiagnosed DM P-value* Number (%) with undiagnosed DM P-value*
Overall 459 (34.5) – 150 (12.7) –
Age (years) 18–24 59 (29.2) 0.596 5 (4.4) 0.007
25–29 35 (32.7) 4 (5.1)
30–34 45 (36.9) 6 (8.0)
35–39 36 (34.0) 12 (11.7)
40–49 80 (34.5) 39 (16.3)
50–59 95 (34.3) 38 (14.5)
60+ 98 (38.3) 46 (15.1)
Sex Male 128 (31.8) 0.160 41 (16.3) 0.053
Female 331 (35.8) 109 (11.8)
Household socio-economic position Very low 100 (43.7) <0.001 24 (12.8) 0.946
Low 130 (39.3) 35 (11.7)
Medium 100 (27.3) 48 (13.3)
High 129 (32.0) 43 (13.0
Highest level of education None/grade 1–2 69 (48.6) <0.001 28 (18.5) 0.147
Grade 3–6 79 (41.4) 32 (11.6)
Grade 7–10 211 (32.9) 63 (12.5)
Grade 11–12 59 (29.4) 26 (11.5)
College/University 41 (26.8) 1 (4.2)
Smoking history Never 391 (33.4) 0.042 125 (13.3) 0.249
Ex-smoker 24 (34.3) 19 (9.3)
Current smoker 44 (49.4) 6 (15.8)
Body Mass Index*** Recommended weight (18.5–24.9) 166 (30.9) 0.298 19 (7.6) 0.047
Underweight (<18.5) 38 (38.8) 5 (13.5)
Overweight (25–29.9) 115 (35.2) 44 (14.8)
Obese (P30) 95 (35.5) 77 (14.0)
HIV status** Negative 329 (34.7) 0.100 131 (13.3) 0.098
Positive 58 (28.7) 10 (8.1)
Self-reported current tuberculosis No 455 (34.5) 0.898 147 (12.6) 0.146
Yes 4 (36.4) 3 (27.7)
Community ZAM1 33 (11.7) <0.001 – –
ZAM2 27 (25.5) –
ZAM3 (rural) 21 (35.6) –
ZAM4 (rural) 15 (57.7) –
ZAM5 25 (31.7) –
ZAM6 27 (42.9) –
ZAM7 46 (48.9) –
ZAM8 43 (55.1) –
ZAM9 25 (44.6) –
ZAM10 15 (25.4) –
ZAM11 35 (37.2) –
ZAM12 32 (39.0) –
ZAM13 28 (38.4) –
ZAM14 33 (56.9) –
ZAM15 (rural) 38 (59.4) –
ZAM16 (rural) 16 (28.6) –
WC1 – – 19 (11.2) 0.007
WC2 – 33 (12.4)
WC3 (rural) – 1 (8.3)
WC4 – 13 (7.0)
WC5 – 15 (25.4)
WC6 (rural) – 36 (17.2)
WC7 – 18 (14.0)
WC8 – 15 (12.7)
DM = diabetes mellitus.
* Pearson’s Chi-squared tests; Total number of participants identified to have diabetes and therefore included in these analyses = 1329 in Zambia and 1179 in Western Cape.
** Based on serology plus self-report for those with no available serology.
*** Grouped according to the International BMI Classification.
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anti-retroviral effects on insulin resistance. The association is
partially explained by adiposity: HIV can cause a reduction of
adiposity, particularly when not on ART, and consequently a
reduction of diabetes risk. Residual confounding by central
obesity is a possible explanation but beyond this the associa-
tion is most likely explained by chance, other residual con-
founding, or bias.
Diabetes is well known to be associated with urban/rural
location [11,12,24,25]. Although not formally explored, an
assessment of this can be made in these data through the
community variable. For both study populations no clear
urban/rural pattern is seen. This could be explained by the
nature of the rural communities that were chosen to take part
in the ZAMSTAR cluster-randomised trial. These communi-
ties are mostly central areas of rural districts rather than
remote villages, and so may not be so different from the
urban areas.
The prevalence of diabetes was found to be higher in the
Western Cape communities than in the Zambian communi-
ties, even for comparable age, sex, relative household socio-
economic position and education, and BMI. This could be
due to differences in dietary habits, levels of physical activity
or genetic factors between the two localities, but as the study
was not designed to explore this we are unable to draw defini-
tive conclusions on the cause of the difference in prevalence
between the two settings.
Misclassification of outcome data could have resulted in
bias. For diabetes, an under-estimate of association is likely
as RBG tests have good specificity but sub-optimal sensitivity
for diabetes diagnosis [27,28]. It is reassuring for the determi-
nation of risk factors, that almost identical associations were
seen when diabetes diagnosis was defined in other ways.
However, for both the prevalence of diabetes and the preva-
lence of undiagnosed diabetes the figures determined in this
study likely represent the minimum true proportions. Indeed,
the proportion of individuals with diabetes who are undiag-
nosed has been reported to be much higher in other parts of
Africa, up to 75% in Northern Africa [13]. The proportion
observed among our Western Cape participants is even com-
parable to that reported from the United States [29]. It is pos-
sible that the comparatively low proportion of the total study
population who have undiagnosed diabetes is partly due to a
low sensitivity of RBGP 11.1 mmol/L for diabetes diagnosis.
Alternative approaches to the study methods could have
been to measure fasting blood glucose or glycated haemoglo-
bin concentrations, or to perform oral glucose tolerance tests.
Any of these methods would have resulted in greater sensitiv-
ity for diabetes diagnosis, but in a large-scale field study with
data collection occurring in the community each of these
approaches would have been logistically challenging and
likely less acceptable to potential participants. Consequently
the likelihood of measurement error and a low uptake of
potential participants would have been high. Therefore it
was felt that the use of RBG measurement for this study
would optimise participant uptake and minimise measure-
ment error.
Even with this approach, the number of participants with
missing data for RBG concentration was substantial. However,
given that the primary focus of data collection was tuberculo-
sis prevalence, for the purposes of the parent study, these
losses are more likely to be due to their lack of prioritisation
during the data collection process rather than due to a lack
of acceptability to participants. Further, in Western Cape par-
ticipants were required to attend a mobile clinic for capillary
Table 5 – Random blood glucose concentration among those with known diabetes.
Random blood glucose concentration (mmol/L) Number (%) of those with known diabetes
All participants Participants on
diabetes treatment
Participants not on
diabetes treatment
Zambian sites
<6.0 385 (44.3) 48 (16.2) 337 (58.7)
6.0–7.8 186 (21.4) 38 (12.8) 148 (25.8)
P7.8 299 (34.4) 210 (71.0) 89 (15.5)
Western Cape sites
<6.0 456 (44.3) 89 (21.3) 367 (60.1)
6.0–7.8 237 (23.0) 73 (17.5) 164 (26.8)
P7.8 336 (32.7) 256 (61.2) 80 (13.1)
Categorisation of glucose concentration based on International Diabetes Federation guidelines for target pre-prandial glucose concentration
(<6.0 mmol/L) and target postprandial glucose concentration (<7.8 mmol/L) [18].
Table 4 – Proportion of those with known diabetes on diabetes treatment.
Diabetes treatment Zambian sites Western Cape sites
Number (%) of those with known diabetes
Any treatment 296 (34.0) 418 (40.6)
Dietary 38 (4.4) 5 (0.5)
Hypoglycaemic tablets 210 (24.1) 338 (32.9)
Insulin 48 (5.5) 75 (7.3)
None 574 (66.0) 611 (59.4)
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blood tests whereas in Zambia the tests were performed in
participants’ homes, which most likely is the explanation
for the higher proportion of missing RBG results seen in Wes-
tern Cape than Zambia. For these reasons the potential for
the missing data to cause bias to the study results, through
being associated with glycaemic concentration, is low.
The accuracy of RBG results obtained in our study is a con-
sideration. Although point-of-care capillary blood glucose
measurement is more rapid, cost-effective and less invasive
than laboratory measurement of plasma glucose concentra-
tion, the latter is considered to be the most accurate method.
Although performance checks were made on test strips and
meters, we have limited quantitation of glucometer charac-
teristics obtained during data collection for this study. Accu-
racy data from other settings are reassuring: a recently
reported study comparing six commonly used point-of-care
blood glucose monitoring systems found the Optium Xceed
system to have the highest level of accuracy, the lowest occur-
rence of error messages and to be least influenced by blood
haematocrit levels [30]. The Optium Xceed system met cur-
rent accuracy criteria set by the International Organization
for Standardization, having >95% of all readings within
±12.5% from the reference at glucose levels >4 mmol/L and
±0.5 mmol/L at glucose levels <4 mmol/L.[30] Consideration
of test accuracy is most relevant to prevalence estimates
obtained in this study as inaccurate results could have led
to estimates that are either too high or too low. However,
there is no reason that glucometer performance would vary
systematically by age or gender or other participant charac-
teristic, and so inaccurate performance would only weaken
associations between participant characteristics and glucose
result. It is reassuring, therefore, that the main risk factors
identified in this study are known to be established risk fac-
tors for diabetes elsewhere [19,20].
The use of random blood glucose concentration to deter-
mine satisfactory control of glycaemia is a major limitation.
When interpreting the proportions in this study of those with
a prior diabetes diagnosis who were found to have an inade-
quate level of glycaemia, it is again important to appreciate
that this is based on a one-off measurement of random blood
glucose concentration, not on a measure of longer-term gly-
caemic control such as glycated haemoglobin. In this large-
scale population-level study setting the measure used and
results obtained are certainly suggestive that glycaemic con-
trol is sub-optimal, but interpretation beyond this should be
made only with caution.
As participants were sampled at random and in suffi-
ciently large numbers, it is possible to generalise these results
to the communities fromwhere the participants came. Gener-
alisation beyond this should be made with caution, as the
communities were not selected at random from the wider
population.
5. Conclusions
The prevalence of diabetes mellitus in the study communities
rivals that seen in high-income settings. The risk factor pro-
file is similar to that seen in Caucasian populations, with
age P50 years and BMIP 30 representing the highest risk
groups for diabetes. The study findings suggest that many of
those with diabetes remain undiagnosed in the community,
particularly among those from a lower socio-economic posi-
tion and with a lower level of education in the Zambian sites.
Even if diagnosed, many of those with diabetes remain sub-
optimally managed. Further studies to guide effective meth-
ods of managing diabetes at the individual and public health
levels in low-income sub-Saharan settings are needed. Timely
diagnosis and management of this long-term non-
communicable disease must be prioritised, with a particular
emphasis on redressing the lack of health equity for the
poorer and less educated.
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